Technology area: Biotechnology & Pharmaceuticals
33 pending office actions • 18 art units • 28 examiners • 0 of 33 (0%) have an AI response strategy ready • 23 patents granted in the last 365 days
ModernaTX Inc. has 33 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 28 distinct examiners and 18 distinct art units, so prosecution is distributed across numerous examination paths while retaining repeated activity in some technical groups.
LARA, CAROLINE MONSERRAT is the busiest examiner, with 3 pending matters. Counsel should pair examiner-specific preparation with a consistent portfolio position on biotechnology claim scope, disclosure support, and response sequencing.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (6%) |
| §103 only | 8 (24%) |
| §102 only | 1 (3%) |
| §112 only | 1 (3%) |
| Double-patenting + other | 11 (33%) |
| Multi-statute (no §101) | 8 (24%) |
| No statute on record | 2 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LARA, CAROLINE MONSERRAT | 3 | 85.7% | +16.7% |
| GILL, RACHEL B | 2 | 65.4% | +28.8% |
| RYAN, DOUGLAS CHARLES | 2 | 38.2% | +48.4% |
| ALAM, DANYAL HASSAN | 2 | 66.7% | +0.0% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.5% |
| FALKOWITZ, ANNA R | 1 | 55.7% | +45.3% |
| LIPPERT, JOHN WILLIAM | 1 | 59.2% | +39.9% |
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
| WHITE, ASHLEY TAYLOR | 1 | 23.8% | +36.7% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17925125 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION, AND METHODS OF USING THE SAME FOR TREATING COVID-19 | LARA, CAROLINE MONSERRAT | 22d overdue |
| 17925114 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION | LARA, CAROLINE MONSERRAT | 16d overdue |
| 18546145 | LNP COMPOSITIONS COMPRISING PAYLOADS FOR IN VIVO THERAPY | LARA, CAROLINE MONSERRAT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18012094 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | RYAN, DOUGLAS CHARLES | 16d overdue |
| 17792554 | METHODS OF PREPARING LIPID NANOPARTICLES | NGUYEN, NGOC-ANH THI | 30d |
| 18812841 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | GILL, RACHEL B | — |
| 18672502 | TERMINALLY MODIFIED RNA | KELLY, ROBERT M | — |
| 18702280 | CUSTOM BACTERIAL STRAIN FOR RECOMBINANT PROTEIN PRODUCTION | WHITE, ASHLEY TAYLOR | — |
| 18592122 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | SHIN, DANA H | — |
| 18569776 | CORONAVIRUS GLYCOSYLATION VARIANT VACCINES | SIFFORD, JEFFREY MARK | — |
| 18284938 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | BROWN, MINDY G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17925125 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION, AND METHODS OF USING THE SAME FOR TREATING COVID-19 | LARA, CAROLINE MONSERRAT | 22d overdue |
| 18012094 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | RYAN, DOUGLAS CHARLES | 16d overdue |
| 17925114 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION | LARA, CAROLINE MONSERRAT | 16d overdue |
| 19410723 | BETACORONAVIRUS mRNA VACCINES | KINSEY WHITE, NICOLE ERIN | — |
| 18812841 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | GILL, RACHEL B | — |
| 18836530 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | FALKOWITZ, ANNA R | — |
| 18796754 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | GILL, RACHEL B | — |
| 18720092 | PROCESSES FOR PREPARING LIPID NANOPARTICLES | LIPPERT, JOHN WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1672 | 5 |
| 1671 | 4 |
| 1635 | 3 |
| 1633 | 3 |
| 1615 | 2 |
| 1638 | 2 |
| 1612 | 2 |
| 1636 | 2 |
| 1600 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19410723 | BETACORONAVIRUS mRNA VACCINES | KINSEY WHITE, NICOLE ERIN | 1672 | §112 | Final Rejection | — | Pending | Dec 05, 2025 |
| 18812841 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | GILL, RACHEL B | 1671 | §102§103§112Other | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18836530 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | FALKOWITZ, ANNA R | 1600 | §103DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18796754 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | GILL, RACHEL B | 1671 | §103§112DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18720092 | PROCESSES FOR PREPARING LIPID NANOPARTICLES | LIPPERT, JOHN WILLIAM | 1615 | §103 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18672502 | TERMINALLY MODIFIED RNA | KELLY, ROBERT M | 1638 | §102§112Other | Non-Final OA | — | Pending | May 23, 2024 |
| 18702280 | CUSTOM BACTERIAL STRAIN FOR RECOMBINANT PROTEIN PRODUCTION | WHITE, ASHLEY TAYLOR | 1653 | §103§112 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18592122 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | SHIN, DANA H | 1635 | §112DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18291707 | PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS | WERTZ, ASHLEE ELIZABETH | 1612 | §103DP | Final Rejection | 34d | Pending | Jan 24, 2024 |
| 18578052 | POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA | RYAN, DOUGLAS CHARLES | 1635 | §102§112DP | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18572490 | POLYNUCLEOTIDES ENCODING URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1 FOR THE TREATMENT OF CRIGLER-NAJJAR SYNDROME | KIEFER, DALTON EDWARD | 1652 | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18543930 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | HASAN, KHALEDA B | 1636 | Other | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18569776 | CORONAVIRUS GLYCOSYLATION VARIANT VACCINES | SIFFORD, JEFFREY MARK | 1671 | §102§103§112Other | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18555087 | RESPIRATORY VIRUS COMBINATION VACCINES | ALAM, DANYAL HASSAN | 1672 | §103§112DP | Final Rejection | 9d overdue | Pending | Oct 12, 2023 |
| 18555130 | INFLUENZA-CORONAVIRUS COMBINATION VACCINES | ALAM, DANYAL HASSAN | 1672 | §103§112DP | Final Rejection | 5d overdue | Pending | Oct 12, 2023 |
| 18284938 | METHODS FOR IDENTIFICATION AND RATIO DETERMINATION OF RNA SPECIES IN MULTIVALENT RNA COMPOSITIONS | BROWN, MINDY G | 1683 | §102§103§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18551704 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | CARR, DEBORAH D | 1691 | §102§103§112 | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18282676 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA | DUNSTON, JENNIFER ANN | 1614 | §103§112DP | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18280362 | VLP ENTEROVIRAL VACCINES | BOESEN, AGNIESZKA | 1672 | §103 | Non-Final OA | — | Pending | Sep 05, 2023 |
| 18546145 | LNP COMPOSITIONS COMPRISING PAYLOADS FOR IN VIVO THERAPY | LARA, CAROLINE MONSERRAT | 1633 | §103 | Final Rejection | — | Pending | Aug 11, 2023 |
| 17928684 | LIPID NANOPARTICLES CONTAINING POLYNUCLEOTIDES ENCODING GLUCOSE-6-PHOSPHATASE AND USES THEREOF | CHONG, KIMBERLY | 1636 | §103§112 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18272512 | VARIANT STRAIN-BASED CORONAVIRUS VACCINES | CHEN, STACY BROWN | 1672 | §101§112 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18314980 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | HILL, MYRON G | 1671 | §103 | Non-Final OA | 72d overdue | Pending | May 10, 2023 |
| 18177455 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | LEONARD, ARTHUR S | 1631 | §103§112DPOther | Non-Final OA | — | Pending | Mar 02, 2023 |
| 18040745 | METHODS OF PREPARING LIPID NANOPARTICLES | SHOMER, ISAAC | 1612 | §103DP | Final Rejection | — | Pending | Feb 06, 2023 |
| 18012094 | LNP COMPOSITIONS COMPRISING MRNA THERAPEUTICS WITH EXTENDED HALF-LIFE | RYAN, DOUGLAS CHARLES | 1635 | §101§102§112DP | Final Rejection | 16d overdue | Pending | Dec 21, 2022 |
| 18008139 | BACTERIAL STRAINS FOR DNA PRODUCTION | TINSLEY, BRENDAN THOMAS | 1634 | §102 | Final Rejection | 1d overdue | Pending | Dec 02, 2022 |
| 17925125 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION, AND METHODS OF USING THE SAME FOR TREATING COVID-19 | LARA, CAROLINE MONSERRAT | 1633 | §103 | Final Rejection | 22d overdue | Pending | Nov 14, 2022 |
| 17925114 | RNA FORMULATIONS FOR HIGH VOLUME DISTRIBUTION | LARA, CAROLINE MONSERRAT | 1633 | §103 | Final Rejection | 16d overdue | Pending | Nov 14, 2022 |
| 17792554 | METHODS OF PREPARING LIPID NANOPARTICLES | NGUYEN, NGOC-ANH THI | 1615 | §103§112 | Final Rejection | 30d | Pending | Jul 13, 2022 |
| 17761420 | CAP GUIDES AND METHODS OF USE THEREOF FOR RNA MAPPING | QIAN, CELINE X | 1637 | §103 | Non-Final OA | — | Pending | Mar 17, 2022 |
| 17277829 | STEROL ANALOGS AND USES THEREOF | MCDOWELL, BRIAN E | 1624 | Other | Non-Final OA | — | Pending | Mar 19, 2021 |
| 17276983 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS | JOHNSON, ALLISON MARIE | 1638 | §103 | Final Rejection | 32d overdue | Pending | Mar 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialModernaTX Inc. has 33 pending office actions as of October 2026, spread across 18 art units and 28 examiners.
Caroline Monserrat Lara has the most, with 3 of ModernaTX Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
